In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $1.73.
According to TipRanks, LeBoyer is an analyst with an average return of -7.8% and a 26.67% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Ocugen, GeoVax Labs, and PDS Biotechnology.
Currently, the analyst consensus on Cocrystal Pharma is a Moderate Buy with an average price target of $10.00, representing a 478.03% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.
The company has a one-year high of $3.29 and a one-year low of $1.33. Currently, Cocrystal Pharma has an average volume of 16.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cocrystal Pharma (COCP) Company Description:
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.
Read More on COCP:
- Cocrystal Pharma reports Q1 EPS (39c) vs (64c) last year
- Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- Cocrystal Pharma (COCP) Q1 Earnings Cheat Sheet
- Cocrystal announces completion of enrollment in Phase 2a study of CC-42344
- Cocrystal Pharma Advances Promising Influenza A Drug
